


RealRate

Blueprint Medicines Corp Rank 22 of 342









PHARMACEUTICAL 2018



Blueprint Medicines Corp Rank 22 of 342



The relative strengths and weaknesses of Blueprint Medicines Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Blueprint Medicines Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 81% points. The greatest weakness of Blueprint Medicines Corp is the variable Other Revenues, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 266%, being 220% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	685,505
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	42,890
Liabilities, Non-Current	0
Other Assets	5,869
Other Compr. Net Income	-251
Other Expenses	0
Other Liabilities	0
Other Net Income	3,128
Other Revenues	21,426
Property and Equipment	24,363
Research and Development	144,687
Selling, General and Administrative Expense	27,986

Output Variable	Value in 1000 USD
Assets	715,737
Liabilities	42,890
Expenses	172,673
Revenues	21,426
Stockholders Equity	672,847
Net Income	-148,119
Comprehensive Net Income	-148,244
Economic Capital Ratio	266%

